Study Group: VELCADE (Bortezomib)(?)
Council Members in this Study Group: 31
Request a survey with this Study Group
Leading Experts in this Study Group
Donald Fleming, MD
Division Head of Hematology and Oncology
Davis Health System, Inc.
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...
Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School
Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at the Dana Farber Cancer Institute in Boston, MA. His clinical focus is on lymphoma, and he is very involved in Phase II/III clinical trials for new compounds, as well as stem cell transplantation.
Assistant Professor of Medicine
University of Pennsylvania Cancer Center
Donald Tsai, MD, PhD, is Assistant Professor of Medicine at the University of Pennsylvania Cancer Center. Dr. Tsai specializes in the treatment of hematological malignancies such as leukemia, multiple myeloma, lymphoma, Hodgkin's disease, myelodysplastic syndromes (MDS), and bone marrow transplantation....
Haitham Al-Okk, MDAssistant Clinical Professor - Hematology-Oncology
Mahr Cancer Center
Haitham Al-Okk, MD, is a Specialist in Hematology-Oncology at Graves-Gilbert Cancer Clinic, a multi-specialty medical group in Kentucky. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology. He specializes in lung, breast, and colorectal...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Satistics are usually used to reveal dramatic differences Patients often misinterpret relative differences for absolute ones patients are willing to do a lot more to get any benefit in cancer outcome
Many studies support EGFR response correlates with rash Many attempts to actually increase the incidence of rash Most patients will use the EGFR treatments despite the rash
Saturn trial attempted to focus on EGFR reative patients Saturn was positive as a maintenance therapy, while concurrent was not
TKI's have been establihed in a small number of refractory solid cancers With slow migration to other venues, we are seeing new applications
Recent Cell Genesys vaccine trial for prostate cancer fails The trial not only shows lack of efficacy, but possible harm from the vaccine arm of the trial
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Lab, Academic Medical Center
- Office Based Private Practice or Clinic
- Biotechnology Manufacturer
- Government/Military Hospital or Clinic
- Other Freestanding Healthcare Facility
Most Common Job Types:
- Physician - Attending Physician
- Director
- Physician - Division Head
- Physician - Director
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms